Clarivate Epidemiology’s coverage of the meningococcal B vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of hospital-treated gram-positive infections (HT-GPIs) comprises epidemiological estimates of nine types of infections—urinary tract infections (UTIs),…
Clarivate Epidemiology’s coverage of BRAF comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…
Clarivate Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase (ALK) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets…
Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of panic disorder comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of neuroendocrine tumor (NET) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of diabetic retinopathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key peripheral arterial disease patient populations, covering 171…
Clarivate Epidemiology’s coverage of restless legs syndrome (RLS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…